Literature DB >> 10683311

The nuclear accumulation of a variant epidermal growth factor receptor (EGFR) lacking the transmembrane domain requires coexpression of a full-length EGFR.

U Marti1, A Wells.   

Abstract

Both the epidermal growth factor (EGF) and its receptor (EGFR) accumulate in the nucleoplasm during liver regeneration. This localization in a nonmembraneous compartment presents a challenge in that the standard form of EGFR is a transmembrane protein and suggests the existence of a variant, soluble form of EGFR. To investigate the localization of such a putative EGFR splice variant, we generated a transmembrane-devoid form of EGFR. We placed this transmembrane-negative [TM(-)] EGFR construct and full-length wild-type (wt) EGFR either in a retroviral transfection vector or in an inducible expression vector. Mouse 3T3 cells, which express endogenous EGFR, were transfected with the TM(-) EGFR construct. The expression of these TM(-) EGFR, detected with a specific antibody against human EGFR using a confocal laser-scanning microscope, was predominantly found in the cytoplasm with no nuclear localization. After an overnight incubation with EGF the TM(-) EGFR accumulated in the nucleus. In mouse NR6 cells, which lack endogenous EGFR, transfected TM(-) EGFR were found in the cytoplasm, but incubation with EGF did not result in a nuclear accumulation of TM(-) EGFR. However, NR6 cells transfected with both TM(-) EGFR and wt EGFR showed nuclear accumulation after EGF treatment. These results suggest that both the wt EGFR and the TM(-) EGFR are required for nuclear accumulation of TM(-) EGFR and may implicate a model of homotypic recognition and translocation of a splice variant of EGFR. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683311     DOI: 10.1006/mcbr.2000.0177

Source DB:  PubMed          Journal:  Mol Cell Biol Res Commun        ISSN: 1522-4724


  12 in total

1.  Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor.

Authors:  Dipak K Giri; Mohamed Ali-Seyed; Long-Yuan Li; Dung-Fang Lee; Pin Ling; Geoffrey Bartholomeusz; Shao-Chun Wang; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

Review 2.  Nuclear trafficking of the epidermal growth factor receptor family membrane proteins.

Authors:  Y-N Wang; H Yamaguchi; J-M Hsu; M-C Hung
Journal:  Oncogene       Date:  2010-05-17       Impact factor: 9.867

3.  HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Yi Liu; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Mol Endocrinol       Date:  2011-08-04

4.  Epidermal growth factor receptors destined for the nucleus are internalized via a clathrin-dependent pathway.

Authors:  Ana Carolina De Angelis Campos; Michele Angela Rodrigues; Carolina de Andrade; Alfredo Miranda de Goes; Michael H Nathanson; Dawidson A Gomes
Journal:  Biochem Biophys Res Commun       Date:  2011-07-29       Impact factor: 3.575

5.  Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver.

Authors:  Xinping Tan; Udayan Apte; Amanda Micsenyi; Emorphia Kotsagrelos; Jian-Hua Luo; Sarangarajan Ranganathan; Dulabh K Monga; Aaron Bell; George K Michalopoulos; Satdarshan P S Monga
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

Review 6.  Biological determinants of radioresistance and their remediation in pancreatic cancer.

Authors:  Parthasarathy Seshacharyulu; Michael J Baine; Joshua J Souchek; Melanie Menning; Sukhwinder Kaur; Ying Yan; Michel M Ouellette; Maneesh Jain; Chi Lin; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-02-27       Impact factor: 10.680

Review 7.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

8.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

Review 9.  Targeting EGFR resistance networks in head and neck cancer.

Authors:  Vladimir Ratushny; Igor Astsaturov; Barbara A Burtness; Erica A Golemis; Joshua S Silverman
Journal:  Cell Signal       Date:  2009-03-01       Impact factor: 4.315

Review 10.  The epidermal growth factor receptor family: biology driving targeted therapeutics.

Authors:  M J Wieduwilt; M M Moasser
Journal:  Cell Mol Life Sci       Date:  2008-05       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.